Cystic Fibrosis Foundation now at 5% or less of BiomX (PHGE)

Rhea-AI Filing Summary

BiomX Inc. (PHGE) is the subject of this Amendment No. 5 to a Schedule 13G/A filed by the Cystic Fibrosis Foundation. The foundation reports beneficial ownership of 174,276 shares of BiomX common stock, representing 1.47% of the class, with sole voting and dispositive power over all reported shares. The filing indicates that the Cystic Fibrosis Foundation now owns 5 percent or less of BiomX’s common stock.

Key Figures

Shares beneficially owned: 174,276 shares Percent of class: 1.47% Sole voting power: 174,276 shares +5 more

8 metrics

Shares beneficially owned 174,276 shares Common Stock of BiomX Inc. beneficially owned by Cystic Fibrosis Foundation

Percent of class 1.47% Percentage of BiomX Inc. common stock class owned by Cystic Fibrosis Foundation

Sole voting power 174,276 shares Shares for which Cystic Fibrosis Foundation has sole power to vote or direct the vote

Shared voting power 0 shares Shares for which Cystic Fibrosis Foundation has shared power to vote or direct the vote

Sole dispositive power 174,276 shares Shares for which Cystic Fibrosis Foundation has sole power to dispose or direct the disposition

Shared dispositive power 0 shares Shares for which Cystic Fibrosis Foundation has shared power to dispose or direct the disposition

Amendment number Amendment No. 5 Amendment number to Schedule 13G filed for BiomX Inc.

CUSIP No. 09090D103 CUSIP for BiomX Inc. common stock, $0.0001 par value per share

Key Terms

beneficially owned, sole voting power, sole dispositive power, percent of class, +1 more

5 terms

beneficially owned financial

"Ownership (a) | Amount beneficially owned: 174,276"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole power to vote or to direct the vote: 174,276"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 174,276"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

percent of class financial

"(b) | Percent of class: 1.47 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

Schedule 13G/A regulatory

"Amendment No. 5 to a Schedule 13G/A filed"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

FAQ

What percentage of BiomX Inc. (PHGE) shares does the Cystic Fibrosis Foundation currently own?

The Cystic Fibrosis Foundation reports beneficial ownership of 1.47% of BiomX Inc. common stock. This corresponds to 174,276 shares and is explicitly disclosed as ownership of 5 percent or less of the class.

How many BiomX Inc. (PHGE) shares are beneficially owned by the Cystic Fibrosis Foundation?

The Cystic Fibrosis Foundation reports 174,276 shares of BiomX Inc. common stock as beneficially owned. It also reports sole voting and sole dispositive power over this same number of shares.

Does the Cystic Fibrosis Foundation share voting or dispositive power over BiomX Inc. (PHGE) shares?

No. The Cystic Fibrosis Foundation reports sole power to vote and dispose of 174,276 shares of BiomX Inc. common stock and 0 shares with shared voting or dispositive power.

What class of BiomX Inc. (PHGE) securities is covered in this Schedule 13G/A Amendment No. 5?

The filing covers BiomX Inc. common stock, $0.0001 par value per share. The CUSIP number for this class of securities is 09090D103, as stated in the disclosure.

Who signed the Schedule 13G/A for the Cystic Fibrosis Foundation regarding BiomX Inc. (PHGE)?

The Schedule 13G/A is signed by Michael Cavadel, identified as Senior Vice President and Chief Legal Officer of the Cystic Fibrosis Foundation, dated 08/20/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 05:16 PM Accepted by SEC EDGAR 08/20/2026 - 05:15 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

BiomX Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

09090D103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 09090D103

1

Names of Reporting Persons

Cystic Fibrosis Foundation

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 174,276.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 174,276.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

174,276.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.5 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BiomX Inc.
(b)	Address of issuer's principal executive offices: 22 Einstein St, 5th Floor, Ness Ziona, ISRAEL, 7414003.
Item 2.
(a)	Name of person filing: Cystic Fibrosis Foundation
(b)	Address or principal business office or, if none, residence: 4550 Montgomery Ave., Suite 1100N, Bethesda MD 20814
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 09090D103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 174,276
(b)	Percent of class: 1.47 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 174,276
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 174,276
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cystic Fibrosis Foundation

Signature:	/s/ Michael Cavadel
Name/Title:	Senior Vice President and Chief Legal Officer
Date:	08/20/2026